(Q42603793)

English

A retrospective analysis of the potential impact of IgG antibodies to agalsidase beta on efficacy during enzyme replacement therapy for Fabry disease

scientific article published on 20 November 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

3 November 2017

A retrospective analysis of the potential impact of IgG antibodies to agalsidase beta on efficacy during enzyme replacement therapy for Fabry disease (English)

1 reference

Europe PubMed Central

3 November 2017

enzyme replacement therapy

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Bernard Bénichou

1

1 reference

Europe PubMed Central

3 November 2017

Sunita Goyal

2

1 reference

Europe PubMed Central

3 November 2017

Crystal Sung

3

1 reference

Europe PubMed Central

3 November 2017

Andrea M Norfleet

4

1 reference

Europe PubMed Central

3 November 2017

Fanny O'Brien

5

1 reference

Europe PubMed Central

3 November 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

20 November 2008

1 reference

Europe PubMed Central

3 November 2017

Molecular Genetics and Metabolism

1 reference

Europe PubMed Central

3 November 2017

96

1 reference

Europe PubMed Central

3 November 2017

1

1 reference

Europe PubMed Central

3 November 2017

4-12

1 reference

Europe PubMed Central

3 November 2017

Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.10.004

7 January 2021

A phase 1/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.10.004

7 January 2021

Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.10.004

7 January 2021

Monitoring the 3-year efficacy of enzyme replacement therapy in fabry disease by repeated skin biopsies

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.10.004

7 January 2021

Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.10.004

7 January 2021

Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.10.004

7 January 2021

Long-term safety and efficacy of enzyme replacement therapy for Fabry disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.10.004

7 January 2021

Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.10.004

7 January 2021

Agalsidase-beta therapy for advanced Fabry disease: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.10.004

7 January 2021

Enzyme replacement therapy in Fabry disease: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.10.004

7 January 2021

Significance of immune response to enzyme-replacement therapy for patients with a lysosomal storage disorder.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.10.004

7 January 2021

Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.10.004

7 January 2021

Assessing kidney function--measured and estimated glomerular filtration rate

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.10.004

7 January 2021

Liquid chromatography-tandem mass spectrometry quantification of globotriaosylceramide in plasma for long-term monitoring of Fabry patients treated with enzyme replacement therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.10.004

7 January 2021

Late abnormal findings on high-resolution computed tomography after Mycoplasma pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.10.004

7 January 2021

Treatment of Fabry disease with different dosing regimens of agalsidase: effects on antibody formation and GL-3.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.10.004

7 January 2021

The Dutch Fabry cohort: diversity of clinical manifestations and Gb3 levels.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.10.004

7 January 2021

Influence of antibody formation on reduction of globotriaosylceramide (GL-3) in urine from Fabry patients during agalsidase beta therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.10.004

7 January 2021

Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.10.004

7 January 2021

Reduced alpha-Gal A enzyme activity in Fabry fibroblast cells and Fabry mice tissues induced by serum from antibody positive patients with Fabry disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.10.004

7 January 2021

The molecular defect leading to Fabry disease: structure of human alpha-galactosidase

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.10.004

7 January 2021

Fabry disease: correlation between structural changes in alpha-galactosidase, and clinical and biochemical phenotypes

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.10.004

7 January 2021

Identifiers

10.1016/J.YMGME.2008.10.004

1 reference

Europe PubMed Central

3 November 2017

1 reference

Europe PubMed Central

3 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42603793&oldid=1962589293"